What is Dimerix?
Founded in 2004 and headquartered in Australia, Dimerix (ASX: DXB) operates within the biopharmaceutical sector, concentrating on novel therapeutic development for global markets. The company's lead product candidate, DMX-200, is being investigated for Diabetic Kidney Disease and FSGS. Dimerix leverages its proprietary Receptor Heteromer Investigation Technology (Receptor-HIT) platform, a scalable technology designed to understand receptor interactions and identify new drug opportunities. This platform has been licensed non-exclusively to Excellerate Bioscience, a UK-based provider of pharmacological assay services.
How much funding has Dimerix raised?
Dimerix has raised a total of $28.7M across 2 funding rounds:
Share Placement
$20M
Other Financing Round
$8.7M
Share Placement (2021): $20M with participation from Merchant Funds Management and Peter Meurs
Other Financing Round (2023): $8.7M led by Mercer Street Partners
Key Investors in Dimerix
Merchant Funds Management
Merchant Funds Management is an Australian investment firm established in 2011, specializing in tailored investment management services for high-net-worth clients. Led by Andrew Chapman, the firm focuses on active portfolio management and risk assessment, aiming to outperform market indices.
Mercer Street Partners
Mercer Street Partners is a real estate investment and asset management firm that employs institutional-level acquisition tactics for middle-market transactions. The firm focuses on disciplined capital deployment and active asset management to achieve superior investment returns.
What's next for Dimerix?
The recent major strategic investment signals a critical growth phase for Dimerix, likely enabling the advancement of its DMX-200 clinical trials and further development of its Receptor-HIT platform. This backing is expected to accelerate the company's progress towards addressing significant unmet medical needs in kidney diseases. The strategic nature of this financing suggests a focus on expanding market reach and potentially forging key partnerships to bring its innovative therapies to patients worldwide.
See full Dimerix company page
